Kevin Longshaw, MD
Family Medicine · Dallas, TXNPI 1013942374
Payments from drug & device makers
Across 895 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Eisai Inc.$4K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- GSK$991
- plus $6K from 32 others
What the payments were for
- Food & beverage$12,56899%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $5,596 |
| Eisai Inc. | 1 | $4,000 |
| Novo Nordisk | 184 | $2,028 |
| Boehringer Ingelheim | 72 | $1,354 |
| Lilly USA, LLC | 91 | $1,080 |
| GSK | 70 | $991 |
| Merck | 54 | $669 |
| Astellas Pharma US Inc | 29 | $534 |
| Abbott | 29 | $506 |
| Amarin Pharma, Inc. | 23 | $477 |
| Pfizer | 49 | $477 |
| Johnson & Johnson | 39 | $442 |
| Sanofi-aventis U.S. LLC | 21 | $375 |
| Bayer | 17 | $287 |
| Amgen | 14 | $243 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $199 |
| Exact Sciences | 9 | $148 |
| Avvisto Therapeutics, LLC | 9 | $144 |
| AbbVie(2 entities) | 8 | $117 |
| Dexcom, Inc. | 7 | $116 |
| Azurity Pharmaceuticals, Inc. | 5 | $98 |
| Arbor Pharmaceuticals, Inc. | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $90 |
| Currax Pharmaceuticals LLC | 5 | $85 |
| Hikma Pharmaceuticals USA | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Genentech USA, Inc. | 4 | $58 |
| Novartis | 4 | $58 |
| Gilead | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Theracosbio, LLC | 2 | $24 |
| Sanofi | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$113
How this compares
$20,700 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 108 | $160,655 |
| OzempicSemaglutide | 81 | $136,148 |
| JardianceEmpagliflozin | 127 | $108,593 |
| FarxigaDapagliflozin Propanediol | 88 | $77,197 |
| MounjaroTirzepatide | 36 | $68,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $37,507 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $36,794 |
| JanuviaSitagliptin Phosphate | 25 | $25,861 |
| EliquisApixaban | 32 | $22,572 |
| MyrbetriqMirabegron | 29 | $16,903 |
| TradjentaLinagliptin | 14 | $9,999 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,477 |
| Rosuvastatin Calcium | 814 | $6,638 |
| Omeprazole | 246 | $5,322 |
| Gabapentin | 173 | $3,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,028 | $296,803189 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $1,354 | $126,069153 claims |
| AstraZenecaFarxiga, Symbicort | $5,596 | $80,680104 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $1,080 | $70,76558 claims |
| GSKTrelegy Ellipta | $991 | $37,50732 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $375 | $36,79427 claims |
| MerckJanuvia | $669 | $25,86125 claims |
| PfizerEliquis | $477 | $22,57232 claims |
| Astellas Pharma US IncMyrbetriq | $534 | $16,90329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.